Lam Daniel D, Przydzial Magdalena J, Ridley Simon H, Yeo Giles S H, Rochford Justin J, O'Rahilly Stephen, Heisler Lora K
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, United Kingdom.
Endocrinology. 2008 Mar;149(3):1323-8. doi: 10.1210/en.2007-1321. Epub 2007 Nov 26.
The neurotransmitter serotonin (5-hydroxytryptamine) is a well-established modulator of energy balance. Both pharmacological and genetic evidence implicate the serotonin 2C receptor (5-HT(2C)R) as a critical receptor mediator of serotonin's effects on ingestive behavior. Here we characterized the effect of the novel and selective 5-HT(2C)R agonist BVT.X on energy balance in obese and lean mice and report that BVT.X significantly reduces acute food intake without altering locomotor activity or oxygen consumption. In an effort to elucidate the mechanism of this effect, we examined the chemical phenotype of 5-HT(2C)R-expressing neurons in a critical brain region affecting feeding behavior, the arcuate nucleus of the hypothalamus. We show that 5-HT(2C)Rs are coexpressed with neurons containing proopiomelanocortin, known to potently affect appetite, in the arcuate nucleus of the hypothalamus of the mouse. We then demonstrate that prolonged infusion with BVT.X in obese mice significantly increases Pomc mRNA and reduces body weight, percent body fat, and initial food intake. To evaluate the functional importance of melanocortin circuitry in the effect of BVT.X on ingestive behavior, we assessed mice with disrupted melanocortin pathways. We report that mice lacking the melanocortin 4 receptor are not responsive to BVT.X-induced hypophagia, demonstrating that melanocortins acting on melanocortin 4 receptor are a requisite downstream pathway for 5-HT(2C)R agonists to exert effects on food intake. The data presented here not only indicate that the novel 5-HT(2C)R agonist BVT.X warrants further investigation as a treatment for obesity but also elucidate specific neuronal pathways potently affecting energy balance through which 5-HT(2C)R agonists regulate ingestive behavior.
神经递质5-羟色胺(5-羟色氨酸)是一种公认的能量平衡调节因子。药理学和遗传学证据均表明,5-羟色胺2C受体(5-HT(2C)R)是5-羟色胺对摄食行为产生影响的关键受体介质。在此,我们研究了新型选择性5-HT(2C)R激动剂BVT.X对肥胖和瘦小鼠能量平衡的影响,并报告称BVT.X能显著减少急性食物摄入量,且不改变运动活性或耗氧量。为了阐明这种作用的机制,我们检查了影响摄食行为的关键脑区——下丘脑弓状核中表达5-HT(2C)R的神经元的化学表型。我们发现,在小鼠下丘脑弓状核中,5-HT(2C)R与含有阿黑皮素原的神经元共同表达,已知阿黑皮素原能有效影响食欲。然后,我们证明在肥胖小鼠中长期输注BVT.X可显著增加阿黑皮素原mRNA水平,并降低体重、体脂百分比和初始食物摄入量。为了评估黑皮质素通路在BVT.X对摄食行为影响中的功能重要性,我们评估了黑皮质素通路受损的小鼠。我们报告称,缺乏黑皮质素4受体的小鼠对BVT.X诱导的食欲减退无反应,这表明作用于黑皮质素4受体的黑皮质素是5-HT(2C)R激动剂对食物摄入量产生影响的必需下游通路。本文提供的数据不仅表明新型5-HT(2C)R激动剂BVT.X作为肥胖治疗药物值得进一步研究,还阐明了5-HT(2C)R激动剂通过其调节摄食行为从而有效影响能量平衡的特定神经元通路。